Amanda Feilding has dedicated her life to the study of the mechanisms underlying the exceptional changes in consciousness, such as those brought about by psychedelic compounds or other mind-altering practices like meditation.
In 1998, Amanda Feilding set up the Beckley Foundation, a non-profit organisation that initiates and supports pioneering research into the therapeutic potential of psychedelic-assisted therapy, while at the same time creating a scientific evidence base for global drug policy reform.
Through many collaborations with leading scientific institutions worldwide, Amanda and the Beckley Foundation have been at the forefront of the psychedelic scientific renaissance, with ground-breaking pre-clinical and clinical research into the mechanisms of action and potential therapeutic benefits of psychoactive substances.
Humanity is facing an ever-worsening mental health epidemic. Everywhere, rates of anxiety, depression, and addiction are on the rise, exerting a vast personal and economic toll. Psychiatry is largely ill-equipped to remedy this situation, and there is an urgent need for novel therapies and treatments.
Psychedelic-assisted therapies, which have been shown to be safe and highly effective for a variety of indications such as depression, addiction, post-traumatic stress disorder (PTSD) and end-of-life existential distress, with both immediate and long-lasting effects, are the perfect candidate for a long overdue breakthrough in mental health.
Fortunately, FDA approval for both psilocybin and MDMA-assisted therapy for the treatment of major depression and PTSD (respectively) appears to be on the horizon. Both treatments have been granted breakthrough therapy by the FDA, a designation that recognises the substantial treatment advantages over existing options for patients with serious or life-threatening diseases, and expedites the drug development process.
There are no other treatments available, and no therapy as effective as to produce such a marked relieve in existential distress, which is why I want to initiate further research into this desperately needed medicine, Feilding says.
In 2008, Amanda Feilding set-up the Beckley/Imperial Research Programme to investigate psychedelics, which she co-directs with Prof David Nutt. Since then, the Programme has produced many pioneering studies, including the first ever scientific investigation into the use of psilocybin-assisted therapy for treatment-resistant depression (TRD).
With currently available treatment options, only around 30% of patients achieve remission, a further 20% respond but do not reach remission, while 50% do not respond at all. Of those non-responders, 30% attempt suicide at least once during their lifetime.
Results from the Beckley/Imperial study demonstrated that psilocybin-assisted therapy was remarkably more efficacious than existing treatments and therapies, with 67% of patients showing significant reductions in their depression scores for five weeks after treatment and positive effects remaining six months after treatment.
In another pilot trial conducted in collaboration with the Johns Hopkins University, psilocybin-assisted psychotherapy helped 80% of chronic smokers to quit tobacco for over six months. This is more than double the success rate of the most effective available nicotine replacement therapy, suggesting drug policy reform is necessary.
The results coming from these and other research projects demonstrate the great potential of psychedelic-assisted therapy to overcome rigid maladaptive patterns of thoughtsand behaviours which underly many psychological disorders. After such promising results, the Beckley Foundation is now seeking funding to explore a wider range of clinical indications and compounds, and to optimise the way these treatments are provided.
The best way to overcome the taboo, and re-integrate psychedelics intothe modern pharmacopoeia, is by undertaking the very best scientific research, Feilding says.
Despite being a leading cause of disability, mental health research still remains underfunded. In the UK, only 5.5% of the health budget is dedicated to mental health research. While increasing the mental health budget is of great importance, a single change to the law could dramatically accelerate the development of effective treatments, namely the rescheduling of psilocybin.
Currently, psilocybin, MDMA, and LSD are all classified as Schedule 1 substances, along with other compounds with no medical use and a high potential for abuse, while more dangerous and highly addictive drugs such as heroin and cocaine are in Schedule 2. Such classification not only negates the scientific evidence rigorously gathered over the past 15 years, but it also impedes scientific and medical advances, imposing exceptionally onerous bureaucratic and financial obstacles, resulting in research on psychedelics costing five to ten times as much as research into other Schedule 2 drugs.
The Beckley Foundation recently published the first policy proposal of its kind, mapping how a carefully regulated, legal market, for MDMA products would work. Drawing on decades of scientific evidence, the proposal closely details the risks, harms and benefits associated with both the therapeutic and the recreational use of MDMA in the context of prohibition, whilst setting out alternative policies for a safer future with a strictlyregulated market.
As the evidence for the medical potential of psychedelics increases, so too does the pressure upon government to reschedule these substances, enabling more clinical research to take place so that these promising treatments can be made available to the patients in need, Feilding says.
After having won the support of leading world figures, including former Presidents, Nobel Laureates, and key notables from the worlds of politics, science and the arts, for the Beckley Foundations 2011 Public Letter, which called on governments and parliaments to abandon the War on Drugs and to embrace drug policy reform based on scientific evidence, Amanda Feilding is now planning to address the UK Prime Minister and Minister of Health in an Open Letter, urging them to move psilocybin to Schedule 2 of the Misuse of Drugs Act (1971).
Reclassifying psilocybin as a Schedule 2 drug would greatly increase access for researchers and enable doctors to prescribe to those in need without any change to legislation governing recreational use, and as such should be considered solely on its significant scientific and medical merit, Feilding says.
Ground-breaking psychedelic therapies have started a paradigm shift in the treatment of mental health, and Amanda Feilding will continue her ongoing efforts to reschedule psychedelics and accelerate their research, in order to open clinics where such treatment can be provided for those in need.
This is a truly exciting time for psychedelic research, and there is a desperate need to support it.
*Please note: This is a commercial profile
Editor's Recommended Articles
Originally posted here:
- Researchers went to festivals to study psychedelic drugs and found they left people feeling happy and connected hours after the high wore off -... - January 22nd, 2020
- Psychedelics and Their 'Mystical Effects' in the Real World - Medscape - January 22nd, 2020
- Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health - Forbes - January 18th, 2020
- Psychedelics have 'extraordinarily potent' anti-inflammatory power. Is there a place for them in mainstream medicine? - Genetic Literacy Project - January 18th, 2020
- Silicon Valley Is Micro-Dosing Magic Mushrooms To Boost Their Careers - Forbes - January 18th, 2020
- NYC To Host Economics Of Psychedelics Investing Summit - Benzinga - January 18th, 2020
- The Best FREE Things to Do for the Next Week - My New Orleans - January 18th, 2020
- Photos of the Stuff That Fascinates People While They're Tripping On LSD - VICE - January 18th, 2020
- Rats on DMT hint at the benefits of psychedelic microdosing - Inverse - December 31st, 2019
- BEYOND LOCAL: Would you ever consider psychedelics to treat PTSD? - SooToday.com - December 31st, 2019
- A Trailblazer of Global Consciousness: Ram Dass Led the Way - Psychology Today - December 31st, 2019
- Magic Mushrooms Move Closer to Mainstream Medicine As VC-Backed Compass Touts Safety, Positive Mood Alteration - Karma - December 13th, 2019
- Miami Clinics Use Ketamine IV Therapy to Help Treat Depression and PTSD - Miami New Times - December 13th, 2019
- Andy Frasco Talks Finding Emotional Balance With Psychedelics On 'Psychedelics Today' Podcast [Listen] - Live for Live Music - November 30th, 2019
- Will psychedelics be available commonly in the near future? - BPhrm Dv - November 30th, 2019
- Letters to the Editor: Psychedelics on their way - Valley Advocate - November 30th, 2019
- Scientists Have a Fascinating New Map of the Human Brain on DMT - VICE - November 30th, 2019
- Hes a fungi: U.S. health agency asks researcher to give it the lowdown on psilocybin mushrooms - The GrowthOp - November 30th, 2019
- A Magic Mushroom Test Case, and the Man Behind It - OZY - November 30th, 2019
- The Two Black Women Helping To Reclaim & Encourage Natural Psychedelics Use In Oakland - Okayplayer - November 2nd, 2019
- Molecule Catalyst and UTM to crowdfund psychedelics research with blockchain - Decrypt - November 2nd, 2019
- On writing: What illuminates a story? - Big Think - November 2nd, 2019
- The future of psychedelic science - Varsity - October 20th, 2019
- Psychedelic Drugs: Researchers experimenting with active agent in magic mushrooms to treat addiction, depression and anxiety - 60 Minutes - CBS News - October 17th, 2019
- Investors hope psychedelics are the new cannabis. Are they high? - The Economist - October 17th, 2019
- Mind Trip: Psychedelics Fighting Depression, Anxiety, Addiction - The National Herald - October 17th, 2019
- Devon Welsh on Growing a Mustache, Psychedelics, and Other Complicated Things - Interview - October 17th, 2019
- Roland Griffiths: 5 Fast Facts You Need to Know - Heavy.com - October 17th, 2019
- How Mushrooms Became Magic - The Atlantic - August 25th, 2017
- Using Mushrooms and LSD to Enhance Creativity - How to Use ... - August 20th, 2017
- LSD - Psychedelics - August 16th, 2017
- This Philosopher Thinks Psychedelic Drugs Lead to the Truth of Experience - Big Think - August 16th, 2017
- Can Psychedelics Treat Bipolar Disorder? - August 13th, 2017
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz - August 13th, 2017
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk - August 8th, 2017
- Daniel Greig, Canadian Drug Policy, Responsibilities, and Psychedelics - The Good Men Project (blog) - August 6th, 2017
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine - August 5th, 2017
- Gonzo Nieto, Drug Policy, Medical and Psychological Effects - The Good Men Project (blog) - August 3rd, 2017
- For children, it's beyond psychedelics - The Hans India - The Hans India - August 1st, 2017
- Modern psychedelic science is reviving lost research and finding new cures - The Plaid Zebra (blog) - August 1st, 2017
- Expanding consciousness - 48 Hills - August 1st, 2017
- What Has Awe Done for Me Lately? - HuffPost - July 31st, 2017
- New book about psychedelics and weird human experiences - Boing Boing - July 26th, 2017
- Psychedelics and Normality - HuffPost - July 26th, 2017
- Reasons to Consider Trying Psychedelics - FoxWeekly - July 25th, 2017
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera - July 22nd, 2017
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER - July 22nd, 2017
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org - July 20th, 2017
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think - July 20th, 2017
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) - July 20th, 2017
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times - July 18th, 2017
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times - July 15th, 2017
- Are psychedelics the new medical marijuana? - WTSP 10 News - July 13th, 2017
- Alameda author's new book examines psychedelic drugs' medical use - East Bay Times - July 12th, 2017
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel ... - Breaking Israel News - July 11th, 2017
- Shrooms Could Be Legalized Sooner Than You Think - VICE - July 11th, 2017
- Parliament George and the Psychedelics? Mayor gets playful lesson on hipness - The Telegraph (blog) - July 8th, 2017
- About Us | Trusted News Source for Psychedelic Research ... - July 7th, 2017
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune - July 5th, 2017
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com - July 4th, 2017
- Is LSD the new coffee? - FactorDaily - July 4th, 2017
- Tune in, Turn on, Stay in School - Study Breaks - July 2nd, 2017
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk - July 2nd, 2017
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist - July 1st, 2017
- The war on drugs is back. Will psychedelic drug research survive? - The Verge - June 29th, 2017
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse - June 27th, 2017
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel - June 24th, 2017
- The Refugee Funding America's Psychedelic Renaissance - VICE - June 24th, 2017
- Majority of Americans ready to embrace psychedelic therapy - YouGov US - June 24th, 2017
- DISMANTLING THE DRUG WAR: Is Cannabis a Gateway to Legalizing Drugs? - Dope Magazine - June 24th, 2017
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press - June 23rd, 2017
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune - June 22nd, 2017
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press - June 22nd, 2017
- Q&A: LaughFest comedian talks science and psychedelics | Athfest ... - Red and Black - June 21st, 2017
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine - June 19th, 2017
- What it's like to take psychedelics in small doses at breakfast | New ... - New Scientist - June 15th, 2017
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service - June 14th, 2017
- Cary Grant was one of the first to benefit from LSD therapy - Quartz - June 11th, 2017
- Stop Policing Psychedelic Science - Motherboard - June 6th, 2017
- America's Trippiest Chemist: Making Psychedelics 'Was Fun' - Motherboard - June 3rd, 2017